Evaluation of a single fixed dose of rasburicase 7.5 mg for the treatment of hyperuricemia in adults with cancer

Pharmacotherapy

Volumn 28, Issue 6, 2008, Pages 685-690

  Reeves, David J ^a   Bestul, Daniel J ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

Fixed dose; Hyperuricemia; Rasburicase; Tumor lysis syndrome; Urate oxidase; Uric acid

Indexed keywords

ALLOPURINOL; CREATININE; RASBURICASE; URIC ACID;

ADULT; AGED; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; CREATININE BLOOD LEVEL; DRUG COST; DRUG DOSE COMPARISON; FEMALE; HUMAN; HYPERURICEMIA; MALE; OPEN STUDY; SINGLE DRUG DOSE; TUMOR LYSIS SYNDROME; URIC ACID BLOOD LEVEL;

ADULT; AGED; FEMALE; HUMANS; HYPERURICEMIA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TUMOR LYSIS SYNDROME; URATE OXIDASE;

EID: 47149108479     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.28.6.685     Document Type: Article

References (14)

1. Davidson MB, Thakkar S, Hix JK, Bhandarkar ND, Wong A, Schreiber MJ. Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med 2004;116:546-54.
2. Bessmertny O, Robitaille LM, Cairo MS. Rasburicase: a new approach for preventing and/or treating tumor lysis syndrome. Curr Pharm Design 2005;11:4177-85.
3. Oldfield V, Perry CM. Rasburicase. Drugs 2006;66:529-45.
4. Sanofi-Synthelabo. Rasburicase (Elitek) package insert. New York, NY; July 2002.
5. Coiffier B, Mounier N, Bologna S, et al. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 study. J Clin Oncol 2003;21:4402-6.
6. Pui CH, Jeha S, Irwin D, Camitta B. Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial. Leukemia 2001;15:1505-9.
7. Jeha S, Kantarjian H, Irwin D, et al. Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek™), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. Leukemia 2005;19:34-8.
8. Hummel M, Buchheidt D, Reiter S, Bergmann J, Hofheinz R, Hehlmann R. Successful treatment of hyperuricemia with low doses of recombinant urate oxidase in four patients with hematologic malignancy and tumor lysis syndrome. Leukemia 2003;17:2542-4.
9. Lee ACW, Li CH, So KT, Chan R. Treatment of impending tumor lysis with single-dose rasburicase. Ann Pharmacother 2003;37:1614-17.
10. Arnold TM, Reuter JP, Delman BS, Shanholtz CB. Use of single-dose rasburicase in an obese female. Ann Pharmacother 2004;38:1428-31
11. Hummel M, Buchheidt D, Reiter S, Bergmann J, Adam K, Hehlmann R. Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia: successful treatment and prevention of TLS with low-dose rasburicase. Eur J Haematol 2005;75: 518-21.
12. McDonnell AM, Lenz KL, Frei-Lahr DA, Hayslip J, Hall PD. Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults. Pharmacotherapy 2006;26:806-12.
13. Liu CY, Sims-McCallum RP, Schiffer CA. A single dose of rasburicase is sufficient for the treatment of hyperuricemia in patients receiving chemotherapy. Leuk Res 2005;29:463-5.
14. Trifilio S, Gordon L, Singhal S, et al. Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia. Bone Marrow Transplant 2006;37:997-1001.